Yung-Ching Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yung-Ching Chen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Yu Liu
Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan
1 shared publication - Jan-Jong Hung
Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan
1 shared publication - Kai-Cheng Hsu
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
1 shared publication - Ming-Jer Young
Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan
1 shared publication - Shao-An Wang
School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
1 shared publication Shih-Min Lin
Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan
1 shared publication
Latest Publications
- Open Access
- 15 March 2024
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 31 (5) , 574-591
USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy
Drug resistance in cancer therapy is the major reason for poor prognosis. Addressing this clinically unmet issue is important and urgent. In this study, we found that targeting USP24 by the specific USP24 inhibitors, USP24-i and its analogues, dramatically activated autophagy in the interphase and mitotic periods of lung cancer cells by inhibiting E2F4 and TRAF6, respectively. USP24 functional knockout, USP24C1695A, or targeting USP24 by USP24-i-101 inhibited drug resistance and activated autophagy in gefitinib-induced drug-resistant mice with doxycycline-induced EGFRL858R lung cancer, but this effect was abolished after inhibition of autophagy, indicating that targeting USP24-mediated induction of autophagy is required for inhibition of drug resistance. Genomic instability and PD-L1 levels were increased in drug resistant lung cancer cells and were inhibited by USP24-i-101 treatment or knockdown of USP24. In addition, inhibition of autophagy by bafilomycin-A1 significantly abolished the effect of USP24-i-101 on maintaining genomic integrity, decreasing PD-L1 and inhibiting drug resistance acquired in chemotherapy or targeted therapy. In summary, an increase in the expression of USP24 in cancer cells is beneficial for the induction of drug resistance and targeting USP24 by USP24-i-101 optimized from USP24-i inhibits drug resistance acquired during cancer therapy by increasing PD-L1 protein degradation and genomic stability in an autophagy induction-dependent manner.
- 15 March 2024
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 31 (5) , 574-591
Open AccessUSP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy
Drug resistance in cancer therapy is the major reason for poor prognosis. Addressing this clinically unmet issue is important and urgent. In this study, we found that targeting USP24 by the specific USP24 inhibitors, USP24-i and its analogues, dramatically activated autophagy in the interphase and mitotic periods of lung cancer cells by inhibiting E2F4 and TRAF6, respectively. USP24 functional knockout, USP24C1695A, or targeting USP24 by USP24-i-101 inhibited drug resistance and activated autophagy in gefitinib-induced drug-resistant mice with doxycycline-induced EGFRL858R lung cancer, but this effect was abolished after inhibition of autophagy, indicating that targeting USP24-mediated induction of autophagy is required for inhibition of drug resistance. Genomic instability and PD-L1 levels were increased in drug resistant lung cancer cells and were inhibited by USP24-i-101 treatment or knockdown of USP24. In addition, inhibition of autophagy by bafilomycin-A1 significantly abolished the effect of USP24-i-101 on maintaining genomic integrity, decreasing PD-L1 and inhibiting drug resistance acquired in chemotherapy or targeted therapy. In summary, an increase in the expression of USP24 in cancer cells is beneficial for the induction of drug resistance and targeting USP24 by USP24-i-101 optimized from USP24-i inhibits drug resistance acquired during cancer therapy by increasing PD-L1 protein degradation and genomic stability in an autophagy induction-dependent manner.